SCHEMBL11965473

SCHEMBL11965473

COC(=O)c1cc2c(F)c(O)ccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
XDH P47989 3/20 0.45
ULK1 O75385 1/20 0.44
FTO Q9C0B1 1/20 0.42
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41
UBE2N P61088 1/20 0.41
GABRE P78334 1/20 0.41
GABRA6 Q16445 1/20 0.41
GABRG1 Q8N1C3 1/20 0.41
GABRG3 Q99928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22647484 0.86 CYP1A2 (0.46) CYP1A2XDHULK1GABRPGABRD
SCHEMBL11965472 0.84 GAA (0.47) CYP1A2XDHULK1KDM4EALDH1A1
SCHEMBL1504255 0.84 HRH4 (0.57) CYP1A2XDHULK1KDM4EALDH1A1
SCHEMBL19332395 0.80 ULK1 (0.50) CYP1A2XDHULK1KDM4EFLT3
SCHEMBL915460 0.78 HRH4 (0.55) CYP1A2XDHULK1FTOKDM4E
SCHEMBL30310659 0.78 HRH4 (0.55) CYP1A2XDHULK1FTOKDM4E
SCHEMBL30310454 0.78 DAO (0.52) CYP1A2XDHULK1KDM4EALDH1A1
SCHEMBL19332317 0.78 DAO (0.52) CYP1A2XDHULK1KDM4EALDH1A1
SCHEMBL22620744 0.78 CYP1A2 (0.44) CYP1A2XDHULK1KDM4EALDH1A1
SCHEMBL23049700 0.77 ULK1 (0.48) CYP1A2XDHULK1KIF11GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778893-B2 (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-15 US disclosed
US-20120196814-A1 (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-02 US disclosed
WO-2011044019-A1 (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196814-A1 (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES CYP11B1, CYP11B2, CYP4B1 CYP1A2 9/4885XDH 1868/4885ULK1 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.